Vas Narasimhan, the CEO of Novartis and the president of industry lobby group Phrma, is warning of the risks to public health from the U.S. government’s reform of drug pricing, saying that the company and its peers have already begun to cut investment in pills for the elderly, The Financial Times’ Hannah Kuchler and Jamie Smyth report. “Every day we’re making pipeline decisions based on the current legislative language and what that’s doing is leading to companies…deprioritizing pills for the elderly, which is not going to be the right thing in the long run for public health,” Narasimhan told the Financial Times. Under President Joe Biden’s Inflation Reduction Act, pills will have a shorter exclusivity period of nine years, compared with 13 years for drugs delivered as infusions.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on NVS:
- Capricor Therapeutics appoints Gotwals to board of directors
- Sandoz receives positive CHMP opinion for multiple sclerosis biosimilar
- Pfizer price target lowered to $42 from $43 at Morgan Stanley
- Novartis’ Sandoz to build Biosimilar Technical Development Center in Slovenia
- Novartis price target raised to CHF 95 from CHF 92 at JPMorgan